Cargando…
T cell epitope: Friend or Foe? Immunogenicity of biologics in context()
Like vaccines, biologic proteins can be very immunogenic for reasons including route of administration, dose frequency and the underlying antigenicity of the therapeutic protein. Because the impact of immunogenicity can be quite severe, regulatory agencies are developing risk-based guidelines for im...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103283/ https://www.ncbi.nlm.nih.gov/pubmed/19619593 http://dx.doi.org/10.1016/j.addr.2009.07.001 |
_version_ | 1783512023648174080 |
---|---|
author | Weber, Constanze A. Mehta, Preema J. Ardito, Matt Moise, Lenny Martin, Bill De Groot, Anne S. |
author_facet | Weber, Constanze A. Mehta, Preema J. Ardito, Matt Moise, Lenny Martin, Bill De Groot, Anne S. |
author_sort | Weber, Constanze A. |
collection | PubMed |
description | Like vaccines, biologic proteins can be very immunogenic for reasons including route of administration, dose frequency and the underlying antigenicity of the therapeutic protein. Because the impact of immunogenicity can be quite severe, regulatory agencies are developing risk-based guidelines for immunogenicity screening. T cell epitopes are at the root of the immunogenicity issue. Through their presentation to T cells, they activate the process of anti-drug antibody development. Preclinical screening for T cell epitopes can be performed in silico, followed by in vitro and in vivo validation. Importantly, screening for immunogenicity is complicated by the discovery of regulatory T cell epitopes, which suggests that immunogenicity testing must now take regulatory T cells into consideration. In this review, we address the application of computational tools for preclinical immunogenicity assessment, the implication of the discovery of regulatory T cell epitopes, and experimental validation of those assessments. |
format | Online Article Text |
id | pubmed-7103283 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71032832020-03-31 T cell epitope: Friend or Foe? Immunogenicity of biologics in context() Weber, Constanze A. Mehta, Preema J. Ardito, Matt Moise, Lenny Martin, Bill De Groot, Anne S. Adv Drug Deliv Rev Article Like vaccines, biologic proteins can be very immunogenic for reasons including route of administration, dose frequency and the underlying antigenicity of the therapeutic protein. Because the impact of immunogenicity can be quite severe, regulatory agencies are developing risk-based guidelines for immunogenicity screening. T cell epitopes are at the root of the immunogenicity issue. Through their presentation to T cells, they activate the process of anti-drug antibody development. Preclinical screening for T cell epitopes can be performed in silico, followed by in vitro and in vivo validation. Importantly, screening for immunogenicity is complicated by the discovery of regulatory T cell epitopes, which suggests that immunogenicity testing must now take regulatory T cells into consideration. In this review, we address the application of computational tools for preclinical immunogenicity assessment, the implication of the discovery of regulatory T cell epitopes, and experimental validation of those assessments. Elsevier B.V. 2009-09-30 2009-07-18 /pmc/articles/PMC7103283/ /pubmed/19619593 http://dx.doi.org/10.1016/j.addr.2009.07.001 Text en Copyright © 2009 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Weber, Constanze A. Mehta, Preema J. Ardito, Matt Moise, Lenny Martin, Bill De Groot, Anne S. T cell epitope: Friend or Foe? Immunogenicity of biologics in context() |
title | T cell epitope: Friend or Foe? Immunogenicity of biologics in context() |
title_full | T cell epitope: Friend or Foe? Immunogenicity of biologics in context() |
title_fullStr | T cell epitope: Friend or Foe? Immunogenicity of biologics in context() |
title_full_unstemmed | T cell epitope: Friend or Foe? Immunogenicity of biologics in context() |
title_short | T cell epitope: Friend or Foe? Immunogenicity of biologics in context() |
title_sort | t cell epitope: friend or foe? immunogenicity of biologics in context() |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103283/ https://www.ncbi.nlm.nih.gov/pubmed/19619593 http://dx.doi.org/10.1016/j.addr.2009.07.001 |
work_keys_str_mv | AT weberconstanzea tcellepitopefriendorfoeimmunogenicityofbiologicsincontext AT mehtapreemaj tcellepitopefriendorfoeimmunogenicityofbiologicsincontext AT arditomatt tcellepitopefriendorfoeimmunogenicityofbiologicsincontext AT moiselenny tcellepitopefriendorfoeimmunogenicityofbiologicsincontext AT martinbill tcellepitopefriendorfoeimmunogenicityofbiologicsincontext AT degrootannes tcellepitopefriendorfoeimmunogenicityofbiologicsincontext |